Cognitive Enhancement Guidelines

Introduction to Cognitive Enhancement

The American Heart Association/American Stroke Association guidelines state that the usefulness of dextroamphetamine in treating cognitive deficits is unclear, with a Class IIb recommendation and Level C evidence, indicating insufficient data to support amphetamine use for cognitive enhancement even in patients with documented cognitive impairment 1
The evidence base for amphetamines is substantially weaker than for cholinesterase inhibitors, such as donepezil, galantamine, and rivastigmine, which have consistent evidence for improving cognition and global assessment in patients with dementia 2, 3, 4

Donepezil, galantamine, and rivastigmine have consistent evidence for improving cognition and global assessment in patients with dementia, with the American College of Physicians recommending their use for patients with dementia 2, 3, 4
Memantine shows consistent improvements in cognition and global assessment, though effect sizes don't reach clinical significance thresholds, according to the American Academy of Neurology 2, 5
Methylphenidate showed no significant cognitive improvements in patients, with only slight attention improvements in one small trial, as reported by the British Medical Journal 6

The American Heart Association/American Stroke Association recommends non-pharmacological interventions, such as cognitive rehabilitation and training strategies, regular physical exercise programs, and enriched environments with cognitive activities, as first-line treatments for cognitive enhancement 1, 6
Regular physical exercise programs have been shown to improve cognitive function in patients, according to the British Medical Journal 6

For patients seeking cognitive enhancement, the American College of Physicians recommends a step-wise approach, starting with non-pharmacological interventions, followed by consideration of cholinesterase inhibitors only if documented cognitive impairment exists, and avoiding both amphetamines and the Mucuna/tyrosine/Alpha-GPC system due to lack of evidence and potential adverse effects 1, 2, 3, 6, 8
The American Academy of Neurology recommends avoiding medications with anticholinergic properties, such as diphenhydramine, cyclobenzaprine, and oxybutynin, which can worsen cognition in older adults 7

Cardiovascular risk factor management, including intensive blood pressure control, has stronger evidence for preventing cognitive decline than any cognitive enhancer, according to the Alzheimer's Association 8
Neither amphetamines nor the Mucuna/tyrosine/Alpha-GPC system should be used in healthy individuals seeking cognitive enhancement, as no evidence supports this indication and both carry risks, as stated by the American College of Physicians 8